Key result
Sotatercept targets vascular remodeling by rebalancing SMAD signaling as the first therapy aiming to cure PAH.
Why the study?
Most pulmonary hypertension treatments only palliate symptoms, making it crucial to identify novel targets directly acting on vascular remodeling to effectively generate curative therapeutic strategies.
The review emphasizes the importance of vascular-immune cell crosstalk and the pulmonary microenvironment in the pathogenesis of pulmonary hypertension, identifying potential novel targets for vascular remodeling.
Pulmonary hypertension is a disease of the lung vasculature, which eventually leads to heart dysfunction. Despite the advances in the discovery and development of new treatments, most of them are aimed to palliate symptoms. Thus, it is crucial to identify novel potential targets directly acting on vascular remodeling. Further understanding of this pathological event is needed to completely describe the disease's mechanisms and effectively generate therapeutical strategies able to cure the disease. Here, we propose an integrative perspective of studying pulmonary hypertension based on the interactions between the vascular cells and their surroundings. This review describes the crosstalk between vascular cells and immune cells in the diseased vasculature, highlighting the central role of this axis and the importance of healthy cell‐to‐cell communication. Furthermore, we discuss the possibility of considering the pulmonary microenvironment as a key pathological factor in pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Navarro‐Llinares et al. (2026) conducted a review in Patients with pulmonary hypertension encompassing various etiologies including idiopathic, heritable, and associated forms, characterized by pulmonary vascular remodeling and inflammation. Sotatercept vs. Placebo or standard of care was evaluated on Vascular remodeling and pulmonary arterial pressure reduction as indicators of treatment efficacy in PAH. Sotatercept targets vascular remodeling by rebalancing SMAD signaling, representing the first therapy aimed at curing pulmonary arterial hypertension beyond symptom palliation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: